April 18th 2024
Researchers were unable to find a significant benefit for patients for the majority of cancer medications given accelerated FDA approval.
Drug Price Negotiations: “We Need to Have an Honest Conversation about Drug Costs”
October 5th 2023Mark Campbell, Pharm.D., RxBenefits’ senior vice president of clinical solutions, talks about how Medicare’s drug price negotiations could have a ripple effect on pharmaceutical company innovation and prices on the commercial side.
ICER Adds New Measures of Value to its Assessment Framework
September 25th 2023ICER adds a more formal process to evaluate the diversity of clinical trials and an assessment of a product’s impact on patient and caregiver productivity. ICER also plans to evaluate how newer methods — which would consider the change of a drug’s price over time and disease severity — can be applied to its value assessment.
Study: How PBMs Impact Drug Prices
September 21st 2023An analysis from 3 Axis has found that PBMs control how much pharmacies are reimbursed. This can vary significantly depending on the PBM contracts with insurers, creating a system with large inconsistencies in the prices that consumers pay for both generics and branded products.
Phentermine/Topiramate More Cost-Effective than Semaglutide for Teen Obesity
September 15th 2023This simulation study also showed that semaglutide was the most effective for weight loss, and researchers said, long-term, savings associated with potential lifelong health improvements may shift the balance of cost-effectiveness.
Dr. Benjamin Rome Discusses Ways to Address High Drug Prices
September 13th 2023Addressing drug affordability and accessibility will involve tackling the interrelated problems of high prices and problematic pharmacy benefit manager practices, says Benjamin N. Rome, M.D., with Brigham and Women’s Hospital in Boston.
Scripius Removes Dupixent from Formulary
September 7th 2023The decision by Scripius (previously Select Health Prescriptions) was made based on the cost of Dupixent, as well as because of an increased demand to use Dupixent for mild atopic dermatitis when the primary patient population is those with moderate to severe disease.